Allervax Cat peptide immunotherapeutic data

In IMUL’s Phase II bronchial challenge trial, 15 of 21 patients given four weekly injections of 750 µg of drug (71 percent) showed significant improvement (p=0.017), as measured by increases in PD-20 at six weeks. PD-20

Read the full 367 word article

How to gain access

Continue reading with a
two-week free trial.